A validated AI software solution for Quantitative assessment of Bone Scans
aBSI is enabled with Artificial Intelligence to mark hotspots and to quantify disease burden – Bone scan index as suggested in PCWG31, is automated in aBSI.
In a prospectively defined multi-institutional phase 3 study with 721 metastatic prostate cancer patients, aBSI was found to be an independent prognostic determinant of overall survival and the study supported using aBSI in the design and eligibility for clinical trials for systemic therapies for metastatic castration-resistant prostate cancer2.
We can offer integrated solutions with both GE Healthcare and Siemens Healthineers!
aBSI is also available for local installation under the name EXINI bone.
aBSI assessments3
- Accurate
- Quantitative
- Reproducible
BSI calculation
The software updates the BSI value, the total skeletal tumor burden,
in real time if editing pre-selected hotspots.
Interested to learn more, book a demo!
Explore aBSI
Learn more about the advantages of Bone Scan Index
Use aBSI
Login
If you already have an account, you can use it to log in to aBSI from your computer.
Publications
Our technology, included in our product aBSI and BONENAVI, is well documented in several studies.
Help
Contact information to our customer support.
Performance and safety
Performance and safety for aBSI and EXINI bone
Our products
Legal
References
- Scher HI, et al. J Clin Oncol. 2016 Apr 20;34(12):1402-18. doi: 10.1200/JCO.2015.64.2702
- Armstrong AJ et al. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018.
- Anand A, et al. Journal of Nuclear Med. 2016 Jan;57(1):41-5.